PE20191745A1 - Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas - Google Patents

Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas

Info

Publication number
PE20191745A1
PE20191745A1 PE2019001213A PE2019001213A PE20191745A1 PE 20191745 A1 PE20191745 A1 PE 20191745A1 PE 2019001213 A PE2019001213 A PE 2019001213A PE 2019001213 A PE2019001213 A PE 2019001213A PE 20191745 A1 PE20191745 A1 PE 20191745A1
Authority
PE
Peru
Prior art keywords
ascorbic acid
chagas disease
treatment
mixture
quinone compounds
Prior art date
Application number
PE2019001213A
Other languages
English (en)
Inventor
Sueli De Oliveira Silva Lautenschlager
Vânia Cristina Desoti
Celso Vataru Nakamura
Valdecir Farias Ximenes
Original Assignee
Ic Medtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ic Medtech Corp filed Critical Ic Medtech Corp
Publication of PE20191745A1 publication Critical patent/PE20191745A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Referido a compuestos de (i) acido ascorbico, enantiomero simple, una mezcla de enantiomeros, o una mezcla de diastereomeros de este, una sal, solvato o hidrato farmaceuticamente aceptable de este; y (ii) un compuesto de quinona, o un enantiomero simple, una mezcla de enantiomeros, o una mezcla de diastereomeros de este, o una sal, solvato, hidrato o profarmaco farmaceuticamente aceptable de este. Tambien se refiere a metodo para tratar, prevenir o aliviar uno o mas sintomas de enfermedad de Chagas.
PE2019001213A 2016-12-06 2017-12-05 Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas PE20191745A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662430758P 2016-12-06 2016-12-06
PCT/US2017/064589 WO2018106623A1 (en) 2016-12-06 2017-12-05 Ascorbic acid and quinone compounds for treating chagas disease

Publications (1)

Publication Number Publication Date
PE20191745A1 true PE20191745A1 (es) 2019-12-12

Family

ID=62491595

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001213A PE20191745A1 (es) 2016-12-06 2017-12-05 Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas

Country Status (10)

Country Link
US (1) US11998523B2 (es)
AR (1) AR110317A1 (es)
BR (1) BR112019011789A2 (es)
CL (1) CL2019001529A1 (es)
CO (1) CO2019007158A2 (es)
CR (1) CR20190323A (es)
EC (1) ECSP19048402A (es)
MX (2) MX2019006593A (es)
PE (1) PE20191745A1 (es)
WO (1) WO2018106623A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468414B1 (en) 2001-02-16 2002-10-22 Hydro-Quebec Method of purification of a redox mediator before electrolytic regeneration thereof
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
US8507555B2 (en) 2006-06-16 2013-08-13 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2009035908A1 (en) * 2007-09-11 2009-03-19 Wyeth Compositions and their use for the treatment of protozoal infections comprising metaflumi zone
WO2009063044A1 (en) * 2007-11-16 2009-05-22 Pharmaq As Treatment of parasite diseases using vitamin k3
EP2456306A4 (en) 2009-07-20 2012-12-26 Summa Health System VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING OESTOLYSIS OR EXTENDING A PROTEST IMPLANT
CA2805745C (en) 2010-07-19 2019-01-15 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
EP2600855A2 (en) 2010-08-04 2013-06-12 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
EP2943188A1 (en) 2013-01-11 2015-11-18 Mayo Foundation for Medical Education and Research Vitamins c and k for treating polycystic diseases
ES2811674B2 (es) 2018-06-06 2024-02-07 Ic Medtech Corp Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria

Also Published As

Publication number Publication date
MX2022008055A (es) 2022-07-27
US11998523B2 (en) 2024-06-04
ECSP19048402A (es) 2019-09-30
US20190343794A1 (en) 2019-11-14
CL2019001529A1 (es) 2019-11-08
CO2019007158A2 (es) 2019-10-09
CR20190323A (es) 2019-11-11
BR112019011789A2 (pt) 2019-10-29
WO2018106623A1 (en) 2018-06-14
MX2019006593A (es) 2019-09-13
AR110317A1 (es) 2019-03-20

Similar Documents

Publication Publication Date Title
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CL2019002204A1 (es) Compuestos inhibidores del vih.
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
EA201692487A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201592182A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
ECSP22019360A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY35400A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
UY36123A (es) Derivados de carboxamida
UY36124A (es) Derivados de carboxamida
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
UY37569A (es) Inhibidores del inmunoproteasoma
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные